文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

BRCA 突变阳性家族中突变阴性女性乳腺癌发病风险不增加。

No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.

机构信息

Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, 825 Eastlake Ave, E., G3-630, Seattle, WA 98109, USA.

出版信息

Breast Cancer Res Treat. 2011 Jan;125(1):169-73. doi: 10.1007/s10549-010-0923-y. Epub 2010 May 11.


DOI:10.1007/s10549-010-0923-y
PMID:20458532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3110729/
Abstract

This analysis addresses risk of breast cancer among women in BRCA-positive families who test negative for the family mutation. We compared the number of prospectively diagnosed breast cancers in 395 mutation-negative women from 28 BRCA1/2-positive families to an age-, race-, and calendar time-specific expected number of breast cancers derived from the SEER 9 Cancer Registry. Study participants contributed a total of 7008.1 person-years of follow-up. The mean age at study entry was 31.3 years; mean follow-up was 17.7 years. Ten women developed breast cancer yielding an observed-to-expected ratio of 0.82 (95% CI 0.39-1.51). Adjustment for possible reduction in breast cancer risk due to oophorectomy by two different methods resulted in O/E ratios in the range of 0.80-0.99. Stratification by degree of relatedness to the nearest mutation carrier did not substantially alter these results, however, women with at least one-first degree relative with breast cancer appeared to have a slightly increased, though not statistically significant, risk of breast cancer (O/E ratio = 1.33, 95% CI 0.41-2.91). Our data suggest that breast cancer risk among mutation-negative women from BRCA1/2 mutation-positive families is similar to that observed in the general population, with a possible slight increase in risk among mutation-negative women with a family history of breast cancer in a first degree relative. Although this is the largest prospective cohort yet assembled to address this important question, the number of breast cancer events is still relatively small.

摘要

本分析针对 BRCA 阳性家族中检测为家族突变阴性的女性的乳腺癌风险。我们将 28 个 BRCA1/2 阳性家族中 395 名突变阴性女性的前瞻性诊断乳腺癌数量与 SEER9 癌症登记处得出的特定年龄、种族和日历时间的预期乳腺癌数量进行了比较。研究参与者共提供了 7008.1 人年的随访。研究入组时的平均年龄为 31.3 岁;平均随访时间为 17.7 年。10 名女性患上了乳腺癌,观察到的与预期的比值为 0.82(95%CI 0.39-1.51)。通过两种不同方法调整因卵巢切除术而可能降低乳腺癌风险,得到的 O/E 比值在 0.80-0.99 之间。按与最近的突变携带者的亲缘关系程度进行分层,并未显著改变这些结果,然而,至少有一名一级亲属患有乳腺癌的女性似乎有略微增加的乳腺癌风险(尽管无统计学意义)(O/E 比值=1.33,95%CI 0.41-2.91)。我们的数据表明,BRCA1/2 突变阳性家族中突变阴性女性的乳腺癌风险与一般人群相似,具有一级亲属乳腺癌家族史的突变阴性女性的风险可能略有增加。尽管这是迄今为止最大的前瞻性队列,用于解决这个重要问题,但乳腺癌事件的数量仍然相对较少。

相似文献

[1]
No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.

Breast Cancer Res Treat. 2010-5-11

[2]
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

JAMA Oncol. 2015-6

[3]
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.

Br J Cancer. 2009-1-27

[4]
Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.

Breast Cancer Res Treat. 2010-1

[5]
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.

J Med Genet. 2013-3-28

[6]
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.

Breast Cancer Res Treat. 2019-2-12

[7]
Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?

Breast Cancer Res Treat. 2011-11-24

[8]
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.

J Natl Cancer Inst. 2010-11-23

[9]
Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families.

Lancet Oncol. 2007-12

[10]
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.

Breast Cancer Res Treat. 2010-3-4

引用本文的文献

[1]
Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country.

Front Oncol. 2022-7-11

[2]
Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?

PLoS One. 2018-4-16

[3]
Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.

Genet Med. 2018-3-22

[4]
No evidence of excessive cancer screening in female noncarriers from mutation-positive families.

Curr Oncol. 2017-12

[5]
Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies.

PLoS One. 2017-2-15

[6]
Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.

Oncol Rep. 2017-3

[7]
Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.

Genet Med. 2016-12

[8]
No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families.

Fam Cancer. 2016-10

[9]
BRCA1 Circos: a visualisation resource for functional analysis of missense variants.

J Med Genet. 2015-4

[10]
Comparison of the screening practices of unaffected noncarriers under 40 and between 40 and 49 in BRCA1/2 families.

J Genet Couns. 2013-8

本文引用的文献

[1]
Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.

Breast Cancer Res Treat. 2010-1

[2]
Cancer statistics, 2009.

CA Cancer J Clin. 2009

[3]
Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families.

Lancet Oncol. 2007-12

[4]
A prospective study of breast cancer risk in relatives of BRCA1/BRCA2 mutation carriers.

J Med Genet. 2007-8

[5]
Phenocopies in breast cancer 1 (BRCA1) families: implications for genetic counselling.

J Med Genet. 2007-4

[6]
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening.

J Med Genet. 2007-1

[7]
Malignancies following bilateral salpingo-oophorectomy (BSO).

Eur J Surg Oncol. 2006-12

[8]
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

J Clin Oncol. 2005-10-20

[9]
Accuracy of cancer family histories: comparison of two breast cancer syndromes.

Genet Test. 2004

[10]
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

Am J Hum Genet. 2003-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索